Contrave (naltrexone/bupropion) / ROVI Pharmaceuticals Laboratories, Currax - LARVOL DELTA

Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a) (clinicaltrials.gov) - P2/3 | N=24 | Completed | Sponsor: Yale University | Active, not recruiting ➔ Completed | N=100 ➔ 24 | Trial completion date: May 2027 ➔ Jun 2026 | Trial primary completion date: May 2027 ➔ Jun 2026

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1) (clinicaltrials.gov) - P2/3 | N=92 | Completed | Sponsor: Yale University | Active, not recruiting ➔ Completed | N=160 ➔ 92 | Trial completion date: Jan 2027 ➔ Jun 2026 | Trial primary completion date: Dec 2025 ➔ Jun 2026

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

Weight Loss Responses to Pharmacotherapy in Breast Cancer Survivors: Results from the Adaptive Nutrition and Exercise Weight loss (A-NEW) Study. (PubMed, Clin Cancer Res) - "Adding Contrave® for BC survivors with minimal initial benefit from BWL results in clinically meaningful weight loss (≥5%) in 42% following 6 months of treatment, which also improves selective cardiometabolic risk factors."

Journal • Breast Cancer • Oncology • Pain • Solid Tumor

Effect of Naltrexone HCl and Bupropion HCl (Contrave) Extended-Release Tablet (NB-ER) for Weight Maintenance in Adult Patients After a 6-Month Intensive Behaviour Modification Program Combined With Meal Replacements. (PubMed, Clin Obes) - "The results from this study demonstrate that after an intensive lifestyle intervention program, treatment with NB-ER for six months prevented weight regain compared to placebo. Additionally, a greater proportion of subjects experienced weight maintenance and less absolute weight regain on NB-ER compared to placebo, supporting the use of NB-ER as an effective option for weight maintenance in patients with significant prior weight loss."

Clinical • Journal • Genetic Disorders • Obesity

Effect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study) (clinicaltrials.gov) - P4 | N=70 | Enrolling by invitation | Sponsor: Carmen Dietvorst | Trial completion date: Mar 2027 ➔ Jul 2027 | Trial primary completion date: Dec 2026 ➔ Jul 2027

Trial completion date • Trial primary completion date • Cardiovascular • Diabetes • Dyslipidemia • Fibrosis • Genetic Disorders • Hepatology • Hypertension • Immunology • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Type 2 Diabetes Mellitus

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE) (clinicaltrials.gov) - P4 | N=8600 | Active, not recruiting | Sponsor: Currax Pharmaceuticals | Recruiting ➔ Active, not recruiting

Adverse events • Enrollment closed • Cardiovascular • Genetic Disorders • Obesity

Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1) (clinicaltrials.gov) - P2/3 | N=160 | Active, not recruiting | Sponsor: Yale University | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a) (clinicaltrials.gov) - P2/3 | N=100 | Active, not recruiting | Sponsor: Yale University | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Obesity

Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial) (clinicaltrials.gov) - P4 | N=150 | Active, not recruiting | Sponsor: The Cleveland Clinic | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2026 ➔ Apr 2028 | Trial primary completion date: Dec 2025 ➔ Apr 2027

Enrollment closed • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

Effect of Mediterranean Diet Combined With Intermittent Fasting on Liver Fibrosis Compared to Naltrexone/Bupropion in People With Cardiometabolic Risk Factors (MEDFAST-study) (clinicaltrials.gov) - P4 | N=70 | Enrolling by invitation | Sponsor: Carmen Dietvorst | Recruiting ➔ Enrolling by invitation | Trial primary completion date: Jul 2026 ➔ Dec 2026

Enrollment status • Trial primary completion date • Cardiovascular • Diabetes • Dyslipidemia • Fibrosis • Genetic Disorders • Hepatology • Hypertension • Immunology • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Type 2 Diabetes Mellitus

Prevalence of Obesity Medications in the Military Health System: An Update from 2022 (OBESITY WEEK 2025) - "Any medications whose primary use was for type 2 diabetes (e.g. Ozempic, Victoza, Mounjaro) were excluded...The most commonly used OMs were Phentermine (45.8%), Wegovy (25.3%), Contrave (19.5%), Qsymia (15.1%), and Zepbound (13.6%)... Despite modest increases in OM utilization within the MHS, overall rates remain low, particularly among active-duty and certain racial and ethnic groups. These findings highlight persistent disparities and suggest a continued need to address policy, access, and provider-level barriers to equitable obesity care."

Cardiovascular • Chronic Kidney Disease • Coronary Artery Disease • Genetic Disorders • Metabolic Disorders • Nephrology • Obesity • Obstructive Sleep Apnea • Renal Disease • Respiratory Diseases • Sleep Apnea • Sleep Disorder • Type 2 Diabetes Mellitus

Researchers also found that CONTRAVE may offer greater utility to certain subgroups of patients, including: (PRNewswire) - "Among those who completed treatment and were ≥90% adherent to medication at week 56, nearly half lost ≥10% of their body weight, 34% reached BMI <30 kg/m2 and 24% reached a healthy waist circumference...Dr. Caroline...found that CONTRAVE improved weight loss in participants with symptoms of mild to moderate depression, more than double those assigned to placebo after 56 weeks of treatment...Dr. Christopher Still, Professor of Medicine at the Geisinger Commonwealth School of Medicine, Danville, Pa., found that in patients who smoked, treatment with CONTRAVE led to greater reductions in both body weight and self-reported smoking compared with placebo, with 47.8% of those treated with CONTRAVE reducing their smoking by week eight. Quitting nicotine is often a trigger for weight gain, so these results are highly clinically relevant."

Clinical data • Obesity

Currax Announces ObesityWeek Data Showing that CONTRAVE Helps Curb Cravings and Offers Marked Effectiveness in Certain Populations with Obesity (PRNewswire) - "Data to be presented by Dr. Robert F. Kushner...show that treatment with CONTRAVE led to improved craving control throughout treatment when compared to placebo. Reduction in baseline cravings was sustained throughout the 56-week treatment timeline and were greatest at eight weeks...The study further showed that patients taking CONTRAVE had an average weight loss of 9.5% at 56 weeks compared to 2.7% for placebo (p <0.0001)."

Clinical data • Obesity

Currax Pharmaceuticals to Spotlight New Research at ObesityWeek 2025 Highlighting Craving Control, Behavioral Adherence, and Subpopulation Outcomes with CONTRAVE (PRNewswire) - "The new data highlights and underscores the differentiated profile of CONTRAVE (naltrexone HCl/bupropion HCl) as an oral, non-GLP-1, combination therapy that helps adults manage weight by reducing appetite and supporting sustainable, long-term outcomes."

Clinical data • Obesity

Anti-obesity Pharmacotherapy and Inflammation (clinicaltrials.gov) - P=N/A | N=30 | Active, not recruiting | Sponsor: Louisiana State University Health Sciences Center in New Orleans | Trial completion date: Jul 2025 ➔ Feb 2026 | Trial primary completion date: Jun 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date • Genetic Disorders • Inflammation • Obesity

Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity (clinicaltrials.gov) - P4 | N=40 | Recruiting | Sponsor: The Royal's Institute of Mental Health Research | Trial completion date: Jul 2025 ➔ Jul 2026 | Trial primary completion date: Jun 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

Drugs and devices for weight management. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparison table: Some drugs for weight management. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal

Contrave, Lybalvi, Auvelity, and Cobenfy: What Do They Have in Common? (PubMed, J Psychiatr Pract) - "This column reviews 4 psychiatric combination products: Contrave (bupropion + naltrexone), Lybalvi (olanzapine + samidorphan), Auvelity (dextromethorphan + bupropion), and Cobenfy (xanomeline + trospium). In each case, the second drug in the combination enhances the efficacy and/or reduces the adverse effects of the first drug. This review illustrates how basic science in pharmacokinetics and brain circuitry was fundamental to the development of these products, particularly in the case of Contrave and Cobenfy."

Journal • Review • Psychiatry

Comparative Effectiveness and Safety of GLP-1 Receptor Agonist versus Traditional Anti-obesity Medications: A Real-world Evidence Study (ENDO 2025) - "Aims: We investigated whether semaglutide demonstrated superior cardiovascular and renal outcomes compared to Qsymia, phentermine, and Contrave in adults with obesity over two years. We conducted a retrospective cohort study using the TriNetX US Collaborative Network database (2015-2024). In this large real-world study, semaglutide demonstrated superior cardiovascular and renal protection compared to other obesity medications, despite increased gastrointestinal side effects. These findings suggest the need for individualized benefit-risk assessment when selecting obesity pharmacotherapy. Future randomized trials should validate these observational findings."

Clinical • HEOR • Real-world • Real-world evidence • Cardiovascular • Chronic Kidney Disease • Constipation • Diabetes • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Nephrology • Obesity • Renal Disease

Currax Expands Access to FDA-Approved Obesity Treatment with Brand Name Contrave with New Cash Price Available via GoodRx (Streetinsider.com) - "Currax Pharmaceuticals LLC...announces today the launch of its latest cost saving initiative with GoodRx, the leading platform for medication savings in the U.S. The national access program introduces a cash pay prescription offer for Contrave, expanding access to affordable weight management medication for more patients, regardless of insurance....Now, patients can access Contrave at a cash price of $199 via GoodRx, regardless of insurance status, allowing them to fill their Contrave prescription at over 70,000 pharmacies across the United States. Through the program, millions of U.S. adults living with obesity and weight-related health issues will have access to obesity treatment."

Commercial • Obesity

Pharmacotherapy as an adjunct to behavioral weight loss treatment in survivors of breast cancer. (ASCO 2025) - P2 | "Contrave can enhance weight loss outcomes in BC survivors who do not attain significant weight loss with diet and exercise modification alone. Further research is needed to understand individuals who benefit most from pharmacotherapy."

Breast Cancer • CNS Disorders • Depression • Fatigue • Genetic Disorders • Mood Disorders • Obesity • Oncology • Pain • Psychiatry • Sexual Disorders • Sleep Disorder • Solid Tumor

Real-world data on the effectiveness of liraglutide (Saxenda) and naltrexone/bupropion (Mysimba) on weight loss outcomes up to 2 years in clinical practice (ECO 2025) - No abstract available

Clinical • Late-breaking abstract • Real-world • Real-world evidence

Comparative Analysis of GLP-1 Receptor Agonists, Traditional Glucose-Lowering Medications and Traditional Anti-obesity Medications on Skeletal Outcomes in Obese Individuals With and Without Type 2 Diabetes: A Five-Year Propensity-Score Matched Cohort Study (ESPE-ESE 2025) - " We conducted a five-year cohort study examining skeletal health outcomes in two distinct populations: obese individuals with type 2 diabetes (T2D) receiving semaglutide versus conventional glucose- lowering medications (sitagliptin, empagliflozin, glipizide), and obese individuals without T2D receiving semaglutide versus traditional anti-obesity medications (Contrave, phentermine, Qsymia). Our findings suggest differential effects of semaglutide on various skeletal health outcomes, with notable protective effects against osteoporosis and gout in obese patients with T2D. These results provide important insights for clinical decision-making in metabolic health management, particularly regarding bone health considerations in anti-obesity medication selection."

Clinical • Diabetes • Genetic Disorders • Gout • Immunology • Metabolic Disorders • Obesity • Osteoarthritis • Osteoporosis • Pain • Rheumatology • Type 2 Diabetes Mellitus

Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial) (clinicaltrials.gov) - P4 | N=150 | Recruiting | Sponsor: The Cleveland Clinic | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity